| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 13, 2017Five-Year, Real-World Data Demonstrate EVAR Outcomes with Endurant® II Stent Graft System Are Comparable in Both Male and Female Patients
DUBLIN and LAS VEGAS - September 13, 2017 - Medtronic plc (NYSE: MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term...
-
Sep 12, 2017New Platform to Offer Enhanced Visualization and Increased Efficiency for Surgery of the Sinuses and Skull Base
DUBLIN - September 12, 2017 - Medtronic plc (NYSE: MDT) today announced the global launch of the StealthStation(TM) ENT, a new surgical navigation system designed for surgeons treating conditions...
-
Sep 12, 2017Data Further Reinforce IN.PACT Admiral DCB as Frontline Option to Address Treatment Challenges in PAD
DUBLIN and LAS VEGAS - September 12, 2017 - Medtronic plc (NYSE: MDT) data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients...
-
Sep 11, 2017
DUBLIN - September 11, 2017 - Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models...
-
Sep 8, 2017Medtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated BalloonClinically-Proven, Durable, Consistent, and Safe Market-Leading DCB Poised to Improve Outcomes for PAD Patients in Japan
DUBLIN - September 8, 2017 - Medtronic plc (NYSE: MDT) today announced that the IN.PACT(TM)Admiral(TM) Drug-Coated Balloon (DCB) received approval from the Japanese Ministry of Health, Labour and...